<DOC>
	<DOC>NCT00407056</DOC>
	<brief_summary>The purpose of this phase 3 open-labeled study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of severe uveitis.</brief_summary>
	<brief_title>Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis</brief_title>
	<detailed_description>The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion in patients with severe endogenous anterior uveitis with an open-labeled, no-controlled and no-randomized design.</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients with a diagnosis of endogenous anterior uveitis or panuveitis Patients with ≥ 50 anterior chamber cells as observed by slit lamp microscopy (criterion for evaluation of signs 4) Patients requiring more frequent instillation of 0.1% betamethasone sodium phosphate ophthalmic solution than the regular frequency specified in its dosage and administration (3 4 times/day) Patients aged ≥ 12 years (on the day of obtaining informed consent) who were able to actuate symptoms Patients giving written informed consent prior to initiation of the study Patients who did not meet all of the above inclusion criteria Patients initiating treatment with systemic administration of any corticosteroid, nonsteroidal antiinflammatory drug, antiphlogistic enzyme or immunosuppressive drug within 2 weeks before instillation of the investigational drug Patients receiving topical injection of any corticosteroid in eyes before instillation of the investigational product(solution formulation: within 1 week before instillation of the investigational product, depot formulation: within 2 weeks before instillation of the investigational product) Patients receiving instillation of any corticosteroid, nonsteroidal antiinflammatory ophthalmic solution or antiphologistic enzyme within 12 hours before instillation of the investigational drug Patients with glaucoma or ocular hypertension Patients with corneal erosion or corneal ulcer Patients with any viral, bacterial or fungal keratoconjunctival disease or suspected with eye infection Patients with allergy to similar drugs of difluprednate Patients requiring use of contact lens during the study period Women who were or might be pregnant, or lactating women Patients participating in another clinical study within 3 months before initiation of the present study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>